A novel strategy for NQO1 (NAD(P)H:quinone oxidoreductase, EC 1.6.99.2) mediated therapy of bladder cancer based on the pharmacological properties of EO9

British Journal of Cancer

Volumn 85, Issue 8, 2001, Pages 1137-1146

  Choudry, G A ^a,b   Stewart, P A Hamilton ^b   Double, J A ^a   Krul, M R L ^c   Naylor, B ^b   Flannigan, G M ^b   Shah, T K ^b   Brown, J E ^a   Phillips, R M ^a  

^a UNIVERSITY OF BRADFORD   (United Kingdom)

^b From the Bradford Hospitals Trust   (United Kingdom)

^c NDDO Oncology ^*  (Netherlands)

Author keywords

Bioreductive drugs; EO9; Mitomycin C: bladder cancer; NQO1

Indexed keywords

5 (1 AZIRIDINYL) 3 HYDROXYMETHYL 2 (3 HYDROXY 1 PROPENYL) 1 METHYL 4,7 INDOLEDIONE; DRUG VEHICLE; MITOMYCIN C; QUINONE DERIVATIVE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE (PHOSPHATE) DEHYDROGENASE (QUINONE);

AEROBIC METABOLISM; ARTICLE; BLADDER CANCER; BLOOD FLOW; CANCER PATIENT; CELL PH; CONTROLLED STUDY; DISEASE ACTIVITY; DRUG ABSORPTION; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG ELIMINATION; DRUG FORMULATION; ENZYME ASSAY; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; PRIORITY JOURNAL;

ANTINEOPLASTIC AGENTS; AZIRIDINES; HUMANS; HYDROGEN-ION CONCENTRATION; IMMUNOHISTOCHEMISTRY; INDOLEQUINONES; INDOLES; QUINONE REDUCTASES; SUBSTRATE SPECIFICITY; URINARY BLADDER; URINARY BLADDER NEOPLASMS;

EID: 0035914266     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1054/bjoc.2001.2056     Document Type: Article

References (39)

1. A rapid and sensitive method for the quantification of microgram quantities of protein utilising the principle of protein-dye binding
2. The autooxidation of reduced forms of EO9
3. Bioreductive agents, hypoxic cells and therapy
4. Enzymology of MMC metabolic activation in tumour tissue. Implications for enzyme directed bioreductive drug development
5. Pharmacological and biochemical determinants of the antitumour activity of the indoloquinone EO9
6. EO9 phase II study in advanced breast, gastric, pancreatic and colorectal carcinoma by the early clinical studies group
7. Reductase enzyme expression across the National Cancer Institute tumour cell line panel: Correlation with sensitivity to MMC and EO9
8. Mechanism of bioreductive alkylation. The example of diazaquinone (AZQ)
9. EO9: A novel bioreductive alkylating indolequinone with preferential solid tumour activity and lack of bone marrow toxicity in preclinical models
10. Intravesical therapy - A critical review
11. Measurement of dicumarol sensitive NADPH: (menadione cytochrome c) oxidoreductase activity results in an artifactual assay of DT-diaphorase in cell sonicates
12. Proliferation and hypoxia in human squamous cell carcinoma of the cervix: First report of combined immunohistochemical assays
13. Potentiation of anti-cancer activity at low intratumoural pH induced by the mitochondrial inhibitor m-iodobenzylguanidine (MIBG) and its analogue benzylguanidine (BG)
14. Up-front chemotherapy for low stage low grade recurrent bladder cancen
15. Elevated DT-diaphorase activity and messenger RNA content in human non small cell lung carcinoma Relationship to the response of lung tumour xenografts to MMC
16. Indoloquinone EO9: DNA interstrand cross linking upon reduction by DTdiaphorase or xanthine oxidase
17. Mechanism for the reductive activation of diazaquinone
18. Intravesical therapy in the management of superficial transitional cell carcinoma of the bladder: The experience of the EORTC GU group
19. A prospective European Organisation for Research and Treatment of Cancer Genitourinary Group randomised trial comparing transurethral resection followed by a single instillation of epirubicin or water in single stage Ta, T1 papillary carcinoma of the bladder
20. Enzymatic and pH modulation of MMC induced DNA damage in MMC resistant HCT 116 human colon cancer cells
21. Bioreductive activation of a series of analogues of 5-aziridinyl3-hydroxymethyl- 1-methyl-2-[1 H-indole-4, 7-dione] prop-β-en-α-ol (EO9) by human DT-diaphorase
22. Inhibition of DT-diaphorase (NAD(P)H:quinone oxidoreductase. EC 1.6.99.2) by 5,6-dimethylxanthenone-4-acetic acid (DMXAA) and flavone8-acetic acid (FAA): Implications for bioreductive drug development
23. In vitro activity of the novel indolequinone EO-9 and the influence of pH on cytotoxicity
24. Evaluation of a novel in vitro assay for assessing drug penetration into avascular regions of tumours
25. Unusually marked hypoxic sensitisation to indolequinone EO9 and MMC in a human colon tumour cell line that lacks NQO1 activity
26. Factors affecting sensitivity to EO9 in rodent and human tumour cells in vitro: DT-diaphorase activity and hypoxia
27. The relative importance of NADPH:cytochrome c (P450) reductase for determining the sensitivity of human tumour cells to the indoloquinone EO9 and related analogues lacking functionality at the C-2 and C-3 positions
28. Phase I and pharmacologic study of the novel indolequinone bioreductive alkylating cytotoxic drug EO9
29. MMC is not metabolised by but is an inhibitor of human kidney NAD(P)H:(quinone acceptor) oxidoreductase
30. Metabolism of MMC by DTdiaphorase. Role in MMC induced DNA damage and cytotoxicity in human colon carcinoma cells
31. PH dependent inactivation of DT-diaphorase by MMC and porfiromycin
32. Immunohistochemical detection of NAD(P)H:Quinone oxidoreductase in human lung and lung tumours
33. Chemosensitivity to the indoloquinone EO9 is correlated with DT-diaphorase activity and gene expression
34. DT-diaphorase activity in normal and neoplastic human tissues: An indicator of sensitivity to bioreductive agents?
35. The effect of intravesical MMC on recurrence of newly diagnosed superficial bladder cancer: A further report with 7 years of followup
36. NAD(P)H:quinone oxidoreductase gene expression in human colon carcinoma cells: Characterisation of a mutation which modulates DT-diaphorase activity and mitomycin sensitivity
37. The role of NAD(P)H:quinone reductase (EC 1.6.99.2, DT-diaphorase) in the reductive bioactivation of the novel indoloquinone antitumour agent EO9
38. Enzyme directed bioreductive drug development revisited: A commentary on recent progress and future prospects with emphasis on quinone anticancer drugs and quinone metabolising enzymes, particularly NQO1
39. Different pH dependency of mitomycin C activity in monolayer and three dimensional cultures